National Cancer Institute awards
Privo a $2.5M grant to optimize it lead product and prepare for its IND.
Privo receives a $2M Award from the National Institute of Dental and Craniofacial Research (NIDCR)
Privo Technologies is honored to receive a Phase 2 award for $2M from the NIDCR SBIR program to further develop its scale-up, chemistry, and manufacturing program.
Privo Technologies Opens New Lab Facility in Peabody, MA
Privo Technologies expands to a new 3,000 square foot facility just outside of Boston, MA. Located at 200 Corporate Place, Suite 6B in Peabody, Massachusetts, the new facility consists of two separate research labs that will be used in...
Privo receives Orphan Designation from the Food and Drug Administration.
Privo Technologies received Orphan Designation for anatomically accessible oral cancers. Receipt of this designation entitles Privo’s current and future oral cancer treatments to additional patent protection, 7 years of drug exclusivity, and tax credits equal to 50% of research...
Privo receives a $220,000 Award from the National Institute of Dental and Craniofacial Research (NIDCR)
Privo Technologies is honored to receive a Phase 1 award for $220,000 from the NIDCR SBIR program to further develop its scale-up, chemistry, and manufacturing program.
Privo Technology’s CEO, Manijeh Goldberg, speaks at IDEASTREAM, MIT Deshpande Center Symposium.
Watch Dr. Goldberg's presentation below regarding localized treatment of cancers in a more safe and effective way and the positive results derived from preclinical studies.
Our Oral Cancer treatment receives MIT’s Innovation Award two years in a row.
The project was awarded over $300,000 in funding from MIT’s Deshpande Innovation Center in 2012 and 2013 to support the company’s drug development activities. We are proud to receive these very competitive awards and honored to be amongst some...
- © Web Design & Development
- © UX Strategy & Digital Branding
